Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Bio-Rad Laboratories Stock Performance
Bio-Rad Laboratories stock opened at $324.07 on Wednesday. The company has a 50 day moving average price of $315.78 and a 200-day moving average price of $307.56. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $384.37. The company has a market capitalization of $9.24 billion, a PE ratio of -31.28 and a beta of 0.95.
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.99. The firm had revenue of $638.50 million during the quarter, compared to the consensus estimate of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The company’s revenue was down 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.00 earnings per share. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.31 earnings per share for the current year.
Analysts Set New Price Targets
Hedge Funds Weigh In On Bio-Rad Laboratories
A number of large investors have recently bought and sold shares of BIO. Brio Consultants LLC bought a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $840,000. Victory Capital Management Inc. raised its stake in Bio-Rad Laboratories by 48.7% in the fourth quarter. Victory Capital Management Inc. now owns 17,671 shares of the medical research company’s stock worth $5,706,000 after buying an additional 5,790 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Bio-Rad Laboratories by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 214,234 shares of the medical research company’s stock worth $69,174,000 after buying an additional 10,040 shares in the last quarter. Principal Securities Inc. bought a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $41,000. Finally, BNP Paribas Financial Markets raised its stake in Bio-Rad Laboratories by 88.8% in the fourth quarter. BNP Paribas Financial Markets now owns 26,925 shares of the medical research company’s stock worth $8,694,000 after buying an additional 12,662 shares in the last quarter. Institutional investors own 65.24% of the company’s stock.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Recommended Stories
- Five stocks we like better than Bio-Rad Laboratories
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- What is a Bond Market Holiday? How to Invest and Trade
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- Options Trading – Understanding Strike Price
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.